6533b821fe1ef96bd127c0b9
RESEARCH PRODUCT
false
subject
0301 basic medicineProteasesAngiogenesisBrain tumorCatalysisInorganic ChemistryExtracellular matrix03 medical and health sciences0302 clinical medicineDownregulation and upregulationGliomaMedicineEpidermal growth factor receptorPhysical and Theoretical ChemistryMolecular BiologySpectroscopybiologybusiness.industryOrganic ChemistryGeneral Medicinemedicine.diseaseComputer Science Applications030104 developmental biology030220 oncology & carcinogenesisImmunologyCancer researchbiology.proteinSignal transductionbusinessdescription
Epidermal growth factor receptor (EGFR) and the mutant EGFRvIII are major focal points in current concepts of targeted cancer therapy for glioblastoma multiforme (GBM), the most malignant primary brain tumor. The receptors participate in the key processes of tumor cell invasion and tumor-related angiogenesis and their upregulation correlates with the poor prognosis of glioma patients. Glioma cell invasion and increased angiogenesis share mechanisms of the degradation of the extracellular matrix (ECM) through upregulation of ECM-degrading proteases as well as the activation of aberrant signaling pathways. This review describes the role of EGFR and EGFRvIII in those mechanisms which might offer new combined therapeutic approaches targeting EGFR or EGFRvIII together with drug treatments against proteases of the ECM or downstream signaling to increase the inhibitory effects of mono-therapies.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2017-06-18 | International Journal of Molecular Sciences |